Improving the standard of care

Bill Anderson Head of Global Product Strategy and Chief Marketing Officer

London, September 2015 This presentation contains certain forward-looking statements. These forward-looking statements may be identified by words such as ‘believes’, ‘expects’, ‘anticipates’, ‘projects’, ‘intends’, ‘should’, ‘seeks’, ‘estimates’, ‘future’ or similar expressions or by discussion of, among other things, strategy, goals, plans or intentions. Various factors may cause actual results to differ materially in the future from those reflected in forward-looking statements contained in this presentation, among others: 1 pricing and product initiatives of competitors; 2 legislative and regulatory developments and economic conditions; 3 delay or inability in obtaining regulatory approvals or bringing products to market; 4 fluctuations in currency exchange rates and general financial market conditions; 5 uncertainties in the discovery, development or marketing of new products or new uses of existing products, including without limitation negative results of clinical trials or research projects, unexpected side-effects of pipeline or marketed products; 6 increased government pricing pressures; 7 interruptions in production; 8 loss of or inability to obtain adequate protection for intellectual property rights; 9 litigation; 10 loss of key executives or other employees; and 11 adverse publicity and news coverage. Any statements regarding earnings per share growth is not a profit forecast and should not be interpreted to mean that Roche’s earnings or earnings per share for this year or any subsequent period will necessarily match or exceed the historical published earnings or earnings per share of Roche. For marketed products discussed in this presentation, please see full prescribing information on our website – www.roche.com All mentioned trademarks are legally protected 2 Performance update

Improving the standard of care

Outlook

3 Q2 2015: Sales growth for fifth consecutive year

10%

8% 8% 7% 7% 6% 6% 6% 6% 6% 5% 5% 4% 5% 4% 4% 4% 4%

2% 2% 0% 0% 1% 0% Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 Q3 Q4 Q1 Q2 11 11 11 11 12 12 12 12 13 13 13 13 14 14 14 14 15 15

All growth rates at Constant Exchange Rates (CER) 4 HY 2015: Strong underlying Group core operating profit & margin

% of sales 40.7% 41.0% 39.2% (+0.4%p 38.5% excl. filgrastim*) 38.1%

+2% at CER (+7%*)

CHFbn 9.5 9.4 9.2 8.3 8.6

HY 2011 HY 2012 HY 2013 HY 2014 HY 2015

CER=Constant Exchange Rates 5 * Excluding sale of filgrastim rights in 2014 at CER 2014: Dividend and payout ratio further increased

CHF Dividend payout ratio (%) 10.00 56.0 55.3 54.7 9.00 54.5 8.00 8.00 51.6 2014 payout ratio: 56.0% 48.6 7.00 44.8 6.00 38.8 34.5 5.00 31.9 4.00 3.00 2.00 1.00 0.00 1990 1992 1994 1996 1998 2000 2002 2004 2006 2008 2010 2012 2014

Payout ratio calculated as dividend per share divided by core earnings per share (diluted); Note: For 1995, a special dividend was paid 6 1 out compoundto mark F. Hoffmann annual growth-La Roche’s rate 100th anniversary in 1996 Performance update

Improving the standard of care

Outlook

7 Roche strategy: Focused on medically differentiated therapies

Regulators: Pharma Dia Optimised benefit / risk ratio Payors: Focus Optimised benefit / cost ratio

MedTech

Premium for innovation for Premium OTC Generics

Differentiation

8 Roche’s approach in specialty care: First and best in class necessary for success

Market share* Undifferentiated products Modest differentiation Medical breakthroughs

Years post launch

Data source: Evaluate Pharma, Decision Resources, Roche/ PMR launch trackers Note: *Market shares represent either % sales of target product relative to sales competing products in similar indications or patient shares from Roche PMR trackers; sales data are actuals (≤ 2013) + consensus broker forecasts (2013-2020) where applicable 9 Roche: Making progress in advancing patient care Recognising innovation 2013-15

Breakthrough Therapy 9 Designations Actemra (Systemic sclerosis) Rank Company # Venetoclax (R/R CLL 17p) YTD 2015 1 Roche 9 (NSCLC) ACE 910 (Hemophilia) 2 GSK 5 Esbriet (IPF) 2 Novartis 5 2014 Lucentis (DR) 3 Merck 4 Atezolizumab (bladder) 3 JNJ 4 Alectinib (2L ALK+ NSCLC) 3 BMS 4 2013 Gazyva (1L CLL)

Source: http://www.focr.org/breakthrough-therapies; CLL=Chronic Lymphocytic Leukemia; NSCLC=Non-Small Cell Lung Cancer; IPF=Idiopathic Pulmonary Hypertension; DR=Diabetic Retinopathy 10 Progressing in Personalised Healthcare 60% of phase 2 & 3 products have PHC component

Phase 2 Phase 3/Registration Marketed

FIXa /FX bispecific MAb MAO-B inh PD-L1 MAb Tarceva® SERD GABRA5 NAM venetoclax (Bcl-2 inh) Zelboraf®

CSF-1R MAb bitopertin alectinib (ALK inh) Erivedge® Ang2 -VEGF MAb basimglurant taselisib Rituxan® ipatasertib V1 receptor antag cobimetinib Gazyva®

crenezumab lebrikizumab Herceptin® lifastuzumab vedotin olesoxime etrolizumab Perjeta® gantenerumab glypican-3 MAb danoprevir Kadcyla®

Flu A MAb ocrelizumab Avastin® LptD antibiotic lampalizumab Xeloda® Esbriet®

Pulmozyme® Oncology Molecular Diagnostics Xolair® Immunology Tissue Diagnostics Infectious Diseases Actemra® Professional Diagnostics Neuroscience Lucentis® Ophthalmology 11 Progressing in Personalised Healthcare 60% of phase 2 & 3 products have PHC component

Phase 2 Phase 3/Registration Marketed

FIXa /FX bispecific MAb MAO-B inh PD-L1 MAb Tarceva® SERD GABRA5 NAM venetoclax (Bcl-2 inh) Zelboraf®

CSF-1R MAb bitopertin alectinib (ALK inh) Erivedge® Ang2 -VEGF MAb basimglurant taselisib Rituxan® ipatasertib V1 receptor antag cobimetinib Gazyva®

polatuzumab vedotin crenezumab lebrikizumab Herceptin® lifastuzumab vedotin olesoxime etrolizumab Perjeta® gantenerumab glypican-3 MAb danoprevir Kadcyla®

Flu A MAb ocrelizumab Avastin® LptD antibiotic lampalizumab Xeloda® Esbriet®

Pulmozyme® Oncology Molecular Diagnostics Xolair® Immunology Tissue Diagnostics Infectious Diseases Actemra® Professional Diagnostics Neuroscience Lucentis® Ophthalmology 12 POPLAR: Atezolizumab increased OS by 7.7 mo in IC2/3 or TC2/3 subgroup

TC3 or IC3 (n = 47) TC2/3 or IC2/3 (n = 105) HRa = 0.49 (0.22, 1.07) HRa = 0.54 (0.33, 0.89) P value = 0.068 P value = 0.014

Median 11.1 mo Median 15.5 mo Median 7.4 mo Median 15.1 mo (6.7, 14.4) (9.8, NE) (6.0, 12.5) (8.4, NE)

TC1/2/3 or IC3 (n = 195) TC0 and IC0 (n = 92) HRa = 0.59 (0.40, 0.85) HRa = 1.04 (0.62, 1.75) P value = 0.005 P value = 0.871

Median 9.2 mo Median 15.5 mo Median 9.7 mo Median 9.7 mo (7.3, 12.8) (11.0, NE) (8.6, 12.0) (6.7, 12.0)

Atezolizumab Docetaxel + Censored 13 aUnstratified HR. Data cut-off May 8, 2015. Atezolizumab and chemo-combos Deep and ongoing effects

Arm C – cb/pac (n=8) Arm D – cb/pem (n=17) Arm E – cb/nab (n=16)

100 100 100 Complete response Complete response Complete response Partial response Partial response Partial response Progressive disease 50 50 Progressive disease 50 Progressive disease Stable disease

Stable disease Stable disease

0 0 0 9 11 9 –16 –7 –12 –17 baseline (%) baseline baseline (%) baseline baseline (%) baseline –22 –23 –25 –31 –31 –21 –21 –22 –50 –43 –50 –38 –50 –45 –41 –42 –47 –43 –50 –53 Maximum SLD reduction from Maximum SLD reduction from

Maximum SLD reduction from –57 –57 –57 –58 –64 –69 –67 –72 –72 –76 –100 –84 –100 –100 –86 –87 100 PR/CR (n=4) 100 PD (n=2) 100 PD (n=2) –100 –100

80 SD (n=4) 80 PR/CR (n=13) 80 PR/CR (n=9) Progression* SD (n=1) SD (n=4) 60 Discontinued 60 Progression* 60 Progression* 40 New lesion 40 Discontinued 40 Discontinued 20 20 New lesion 20 New lesion 0 0 0 –20 –20 –20 –40 –40 –40 –60 –60 –60

Change in SLD from SLD (%)baseline Change in –80

–80 from SLD (%)baseline Change in –80 Change in SLD from SLD (%)baseline Change in –100 –100 –100

0 42 84 126 168 210 252 294 336 378 420 450 0 42 84 126 168 210 252 294 336 378 420 450 0 42 84 126 168 210 252 294 336 378 420 450

Time on study (days) Time on study (days) Time on study (days)

14 Includes all patients dosed by 10 Nov 2014; data cut-off: 10 Feb 2015; SLD, sum of longest diameters; *PD for reasons other than new lesions The 7 steps of the Cancer-Immunity Cycle guide our prioritization framework for Atezolizumab

Step 1: Release of Cancer Cell antigens: - ex: Atezo + chemo, Gazyva, aCD40

Step 2 & 3: Cancer antigen presentation & priming and activation - ex: Atezo + interferon, OX40

Steps 4 & 5: Trafficking & inflitration of T cells to tumours - ex: Atezo + Avastin, aCSF1R,

Steps 6 & 7: Recognition of cancer cells by T cells & killing of cancer cells - ex: Atezo + Meki, IDOi, aOX40

Chen and Mellman. Immunity 2013 15 Progressing in Personalised Healthcare 60% of phase 2 & 3 products have PHC component

Phase 2 Phase 3/Registration Marketed

FIXa /FX bispecific MAb MAO-B inh PD-L1 MAb Tarceva® SERD GABRA5 NAM venetoclax (Bcl-2 inh) Zelboraf®

CSF-1R MAb bitopertin alectinib (ALK inh) Erivedge® Ang2 -VEGF MAb basimglurant taselisib Rituxan® ipatasertib V1 receptor antag cobimetinib Gazyva®

polatuzumab vedotin crenezumab lebrikizumab Herceptin® lifastuzumab vedotin olesoxime etrolizumab Perjeta® gantenerumab glypican-3 MAb danoprevir Kadcyla®

Flu A MAb ocrelizumab Avastin® LptD antibiotic lampalizumab Xeloda® Esbriet®

Pulmozyme® Oncology Molecular Diagnostics Xolair® Immunology Tissue Diagnostics Infectious Diseases Actemra® Professional Diagnostics Neuroscience Lucentis® Ophthalmology 16 Three major types of Multiple Sclerosis

Relapse-Remitting (RRMS) Mainly inflammatory (60-65%) Clearly defined relapses (attacks) with remissions initially returning • High unmet need: to baseline but gradually result in sustained disability • high efficacy therapies have major safety issues • diagnosis and classification is Inflammatory / Degenerative Secondary Progressive difficult, often retrospective and (SPMS) (20-25%) can take 2-5 years Initial RRMS followed by disability accumulation. Still experience relapses which eventually stop • Treatment decisions concentrated Disability

Relapse No Relapse mainly in MS centers/hospitals

• Advocacy groups powerful in access Mainly degenerative Primary Progressive (PPMS) (10-15%) Slow but nearly continuous worsening of disease from outset (no relapses)

Time 17 Adapted from Lublin 1996, Arnold 2004 Ocrelizumab: Positive phase 3 results confirm central role of B cells in MS

Complement dependent cytotoxicity (CDC) OCRELIZUMAB

Antibody-dependent cellular Reduction cytotoxicity (ADCC) Study Endpoint versus Rebif®

Primary Annualized Relapse Rate Apoptosis Confirmed Disability ü Progression Secondary ü MRI endpoints Antibody-dependent cellular ü phagocytosis (ADCP)

Phase 3 OPERA I/II results in RMS • Superiority vs. Rebif® on primary and Targeted product profile major secondary endpoints achieved • targeting CD20+ B cells • Adverse events (including serious ® • Selective depletion of a subset of B cells leaving infections) similar to Rebif the ability to generate new B cells intact Phase 3 ORATORIO in PPMS • Administered by IV twice yearly • First investigational medicines to show efficary in PPMS 18 SOC=standard of care; MS=multiple sclerosis; RMS=relapsing forms of MS; PPMS= primary progressive MS; Rebif® (Interferon beta-1a) Multiple major pivotal trials reading out near term Significant filing and launch activities ahead

Market Incremental Market Year Molecule opportunity infrastructure characteristics Alectinib Medium Low Speciality

Cotellic/ Braf Small Low Speciality 2015 Venetoclax Potentially large Low Speciality Ocrelizumab Large Medium- high Speciality Atezolizumab Large Medium Speciality

Lebrikizumab Large Medium-high Specialty 2016 APHINITY Large Low Specialty GOYA Large Low Specialty ACE 910 Large Medium Speciality 2017 Lampalizumab Large Medium Speciality GALLIUM Large Low Specialty Taselisib (PI3Ki) Large Low Speciality 2018 Idasanutlin Medium Low Speciality (MDM2)

Oncology Neuroscience Ophthalmology Immunology 19 Small: up to CHF 0.5 bn; medium= CHF 0.5 to CHF 1bn; large > CHF1bn Performance update

Improving the standard of care

Outlook

20 Planned key data presentations in H2 2015

Vienna, 25-29 Sep Barcelona, 7-10 Oct San Francisco, 18-21 Nov San Antonio, 8-12 Dec

Atezolizumab Ocrelizumab Atezolizumab Atezolizumab • UBC: IMvigor 210 Ph II1 • RMS: OPERA I / II Ph III • Melanoma: Combo with • TNBC: Combo with • NSCLC: POPLAR Ph II1,2 • PPMS: ORATORIO Ph III Zelboraf Ph Ib abraxane Ph Ib • NSCLC: BIRCH Ph II1 (abstracts submitted) (abstracts submitted) • NSCLC: Chemo combos update2 Cobimetinib + Zelboraf • BRAF+Melanoma: Alectinib coBRIM efficacy update 2 • ALK+NSCLC: Ph II update (abstracts submitted)

1 “Data not yet in-house; planned to be submitted to an up-coming congress”; 2 Potentially at World Conference on Lung Cancer (WCLC) 2015 UBC=Urinary Bladder Cancer; NSCLC=Non-Small Cell Lung Cancer; RMS=Relapsing forms of Multiple Sclerosis; TNBC=Triple Negative Breast Cancer 21 2015 outlook

Group sales growth1 Low to mid-single digit

Core EPS growth1 Ahead of sales growth2

Dividend outlook Further increase dividend in Swiss francs

1 At constant exchange rates 22 2 Excluding sale of filgrastim rights in 2014 Doing now what patients need next